Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02733263 · ClinicalTrials.gov registry record · NA
Resistant Maltodextrin Supplementation: Gastrointestinal Health
A NA study, sponsored by University of Florida.
- Completed
- Registry status
- NA
- Development phase
- 64
- Enrollment target
NCT02733263: Completed NA study, sponsored by University of Florida.
NCT02733263 is a NA study that has completed, run by University of Florida. The registered enrollment target is 64 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02733263, a NA study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
Study Summary
Resistant maltodextrin (RMD) is an indigestible water soluble fiber that increases fecal bulk by enhancing growth of specific microbial populations; however the effect of RMD on bifidobacteria and total fecal weight is not clear. The purpose of this research study is to determine whether incorporating about ¼ cup of a fiber supplement into the diet will induce beneficial changes in gastrointestinal function, the fecal microbiota profile (increased number of healthy bacteria in stool) and immune processes resulting in improved quality of life.
Primary Outcome
The mean of the change between baseline and final time points in stool bifidobacteria counts \[log(CFU)\] was compared for each study arm.
Interventions
- DIETARY_SUPPLEMENT 15 g RMD
- DIETARY_SUPPLEMENT 25 g RMD
- DIETARY_SUPPLEMENT 0 g RMD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2016-05 |
| Est. Completion | 2016-11 |
| Phase | NA |
What the finished NCT02733263 record still lists
NCT02733263 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 3 interventions - of which 15 g RMD is the first listed.
NCT02733263 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02733263 about?
NCT02733263 is a clinical study titled "Resistant Maltodextrin Supplementation: Gastrointestinal Health". Resistant maltodextrin (RMD) is an indigestible water soluble fiber that increases fecal bulk by enhancing growth of specific microbial populations; however the effect of RMD on bifidobacteria and total fecal weight is not clear. The purpose of this research study is to determine whether incorporati...
What is the current status of trial NCT02733263?
This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2016-05. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02733263?
The interventions under investigation include: 15 g RMD (DIETARY_SUPPLEMENT), 25 g RMD (DIETARY_SUPPLEMENT), 0 g RMD (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02733263?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02733263's enrollment target sits among peer trials
64 1147th of 2000 higher than 844 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia